Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ypsomed Holding AGXSWX:YPSN -1.63%92 3-Year EPS without NRI Growth Rate is 62.20% as of Mar. 2026, which is 141% above its 10-year median of 25.85. GuruFocus rates XSWX:YPSN with a GF Score™ of 92/100 and a GF Value™ of CHF394.03 (Fairly Valued). The stock has 4 warning signs investors should review. Among 662 Medical Devices & Instruments companies, Ypsomed Holding AG ranks better than 92.3% on this metric.
During the past 12 months, Ypsomed Holding AG's average EPS without NRI Growth Rate was 154.30% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 62.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 106.70% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 11.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Ypsomed Holding AG was 191.80% per year. The lowest was -89.90% per year. And the median was 25.85% per year.
Ypsomed Holding AG (XSWX:YPSN) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ypsomed Holding AG 3-Year EPS without NRI Growth Rate Related Terms
XSWX:YPSN vs ISRG, BDX, RMD: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ypsomed Holding AG 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ypsomed Holding AG's 3-Year EPS without NRI Growth Rate falls into.
Ypsomed Holding AG 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 62.20% mean?
Ypsomed Holding AG (XSWX:YPSN) has a 3-Year EPS without NRI Growth Rate of 62.20% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ypsomed Holding AG and its competitors. This is 141% above median its historical median of 25.85. According to the industry distribution chart, Ypsomed Holding AG ranks #51 out of 662 companies in the Medical Devices & Instruments industry, placing it in the top 7.7%.
Is Ypsomed Holding AG's 3-Year EPS without NRI Growth Rate too high?
Ypsomed Holding AG's current 3-Year EPS without NRI Growth Rate of 62.20% is 141% above median its 10-year median of 25.85. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.05. Ypsomed Holding AG's value of 62.20% is 672.7% above this industry median. Based on the distribution chart, Ypsomed Holding AG ranks #51 out of 662 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ypsomed Holding AG has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's 3-Year EPS without NRI Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ypsomed Holding AG ranks #51 out of 662 companies for 3-Year EPS without NRI Growth Rate. This places Ypsomed Holding AG in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 8.05. Ypsomed Holding AG's value of 62.20% is 672.7% above this benchmark. While the company's 10-year median is 25.85 vs. the industry median of 8.05, Ypsomed Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.05, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ypsomed Holding AG's current 3-Year EPS without NRI Growth Rate of 62.20% is 672.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ypsomed Holding AG and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current 3-Year EPS without NRI Growth Rate is 62.20%, which is 141% above median its own 10-year median of 25.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Fairly Valued. The stock's GF Value™ is CHF394.03, compared to a current price of CHF351.00 — trading 10.9% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 62.20%, which is 141% above median its 10-year median of 25.85 and 672.7% above the Medical Devices & Instruments industry median of 8.05. Ypsomed Holding AG's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current 3-Year EPS without NRI Growth Rate is 62.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued.
The current stock price of CHF351.00 is trading 10.9% below its estimated GF Value™ of CHF394.03.
GuruFocus considers Ypsomed Holding AG to be Fairly Valued.
Key valuation signals for XSWX:YPSN:
3-Year EPS without NRI Growth Rate: 62.20% (141% above median its 10-year median of 25.85)
GF Value™: CHF394.03 vs. price of CHF351.00 (10.9% below fair value)
Industry Position: 672.7% above the Medical Devices & Instruments median (#51 of 662)
No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
92GF Score
Get the complete analysis for XSWX:YPSN
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:YPSN has been successfully added to your 
